Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro

V ShindeAnthonet KoenZ HoosainM ArcharyQ BhoratLee FairlieAylin Oommen JoseDishiki KalonjiE et alShabir Madhi2025-04-13WOS2164-5515https://hdl.handle.net/10539/44736Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized croJournal Article